A REAL-WORLD ANALYSIS OF TREATMENT PATTERNS FOR FIRST-LINE IMMUNOTHERAPIES AMONG DANISH PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND PD-L1 EXPRESSION $50%

被引：0
|
作者：
Clugston, D. M. [1 ]
Beck, C. [2 ]
Bjerregaard, B. K. [3 ]
Kristensen, E. S. [4 ]
机构：
[1] Roche Pharmaceut AS, Copenhagen, Denmark
[2] Roche Pharmaceut AS, Copenhagen 84, Denmark
[3] IQVIA Denmark, Copenhagen, Denmark
[4] IQVIA, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD53
引用
收藏
页码：S514 / S514
页数：1
相关论文
共 50 条
  • [31] Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Wu, Chih-Ying
    Ku, Wen-Hui
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Su, Kang-Yi
    Yu, Sung-Liang
    Chang, Gee-Chen
    JOURNAL OF IMMUNOTHERAPY, 2018, 41 (06) : 292 - 299
  • [32] Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50%
    Zarogoulidis, Paul
    Papadopoulos, Vasilis
    Maragouli, Elena
    Papatsibas, George
    Sardeli, Chrysanthi
    Man, Yan-Gao
    Bai, Chong
    Huang, Haidong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S28 - S30
  • [33] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [34] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Katakami, Nobuyuki
    Hirata, Yukio
    ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
  • [35] Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
    Perea, J.
    Gomez, E.
    Escriva, C.
    Pellicer, A. V.
    Rodriguez, P. Llor
    Iranzo, J.
    Vidal, O. J. Juan
    Sanchez, J. Garcia
    Montagud, G. Suay
    Mico, A. Ferrero
    Diaz, J. Linares
    Sepulveda, N. Gomez
    Hernandez, E. Soria
    Gallego, J. Esteve
    Carrasco, C.
    Gaudens, P. Capdevila
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S72 - S73
  • [36] A real-world study of PD-L1 testing patterns and PD-1/PD-L1 inhibitor therapy in patients with metastatic non-small cell lung cancer: An analysis of the Sotiria Hospital lung cancer registry
    Charpidou, Andriani
    Syrigos, Nikolaos K.
    Kokkotou, Eleni
    Stournara, Lamprini
    Mani, Maria
    Tsagouli, Sofia
    Burke, Thomas
    Spanoudi, Filio
    Desiniotis, Andreas
    Dimitriadis, Ioannis
    Gkiozos, Ioannis
    PNEUMON, 2024,
  • [37] COSTS OF CARE FOR FIRST-LINE (1L) TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A REAL-WORLD CLAIMS ANALYSIS
    Kish, Jonathan
    Chopra, Dhruv
    Liassou, Djibril
    Lubinga, Solomon
    Hartman, John
    Feinberg, Bruce
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A437 - A438
  • [38] Real-world prospective data of small biopsy samples for tumor PD-L1 expression in non-small cell lung cancer
    Morikawa, K.
    Tsunoda, A.
    Inoue, T.
    Mineshita, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
    Garcia Campelo, M. R.
    Arriola Aperribay, E.
    Campos Balea, B.
    Lopez-Brea, M.
    Fuentes Pradera, J.
    de Castro Carpeno, J.
    Aguado, C.
    Perez Parente, D.
    de Oro-Pulido, F.
    Rodriguez Abreu, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S1413 - S1414
  • [40] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
    Peng, Jianfeng
    Zhang, Lemeng
    Wang, Liping
    Feng, Hui
    Yao, Dongmei
    Meng, Rui
    Liu, Xiaomei
    Li, Xiaohua
    Liu, Ningbo
    Tan, Bingxu
    Huang, Zhaoqin
    Li, Shanshan
    Meng, Xiangjiao
    RADIATION ONCOLOGY, 2023, 18 (01)
12345